The effects of Δ 9-tetrahydrocannabinol and cannabidiol alone and in combination on damage, inflammation and in vitro motility disturbances in rat colitis

British Journal of Pharmacology

Volumn 160, Issue 3, 2010, Pages 712-723

  Jamontt, J M ^a   Molleman, A ^a   Pertwee, R G ^b   Parsons, M E ^a  

^a UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

9 tetrahydrocannabinol; Cannabidiol; Cannabinoids; Colitis; Inflammation; Inflammatory bowel disease; Motility; Sulphasalazine

Indexed keywords

CANNABIDIOL; DRONABINOL; MYELOPEROXIDASE; SALAZOSULFAPYRIDINE; PEROXIDASE; TETRAHYDROCANNABINOL; TRINITROBENZENESULFONIC ACID;

ACUTE DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHOLINERGIC NERVE; COLITIS; COLON INJURY; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; ENZYME ACTIVITY; IN VITRO STUDY; INTESTINAL DYSMOTILITY; INTESTINE MOTILITY; MONOTHERAPY; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; RAT; ANIMAL; COLON; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECT; GASTROINTESTINAL MOTILITY; INFLAMMATION; MALE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; WISTAR RAT;

ANIMALS; CANNABIDIOL; COLITIS; COLON; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; GASTROINTESTINAL MOTILITY; INFLAMMATION; MALE; PEROXIDASE; RATS; RATS, WISTAR; SULFASALAZINE; TETRAHYDROCANNABINOL; TRINITROBENZENESULFONIC ACID;

EID: 77952593814     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2010.00791.x     Document Type: Article

References (54)

1. Alexander SP, Mathie A, Peters JA (2009). Guide to Receptors and Channels (GRAC), 4th edition. Br J Pharmacol 158 (Suppl. 1 S1 S254.
2. Anderson PF, Jackson DM, Chesher GB (1974). Interaction of delta9-tetrahydrocannabinol and cannabidiol on intestinal motility in mice. J Pharm Pharmacol 26 : 136 137.
3. Appleyard CB, Wallace JL (1995). Reactivation of hapten-induced colitis and its prevention by anti-inflammatory drugs. Am J Physiol 269 : G119 G125.
4. Arribas B, Rodriguez-Cabezas ME, Camuesco D, Comalada M, Bailon E, Utrilla P et al. (2009). A probiotic strain of Escherichia coli, Nissle 1917, given orally exerts local and systemic anti-inflammatory effects in lipopolysaccharide-induced sepsis in mice. Br J Pharmacol 157 : 1024 1033.
5. Baumgart DC, Sandborn WJ (2007). Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 369 : 1641 1657.
6. Borrelli F, Aviello G, Romano B, Orlando P, Capasso R, Maiello F et al. (2009). Cannabidiol, a safe and non-psychotropic ingredient of the marijuana plant Cannabis sativa, is protective in a murine model of colitis. J Mol Med 87 : 1111 1121.
7. Boughton-Smith NK, Wallace JL, Morris GP, Whittle BJ (1988). The effect of anti-inflammatory drugs on eicosanoid formation in a chronic model of inflammatory bowel disease in the rat. Br J Pharmacol 94 : 65 72.
8. Bradley PP, Priebat DA, Christensen RD, Rothstein G (1982). Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 78 : 206 209.
9. Capasso R, Borrelli F, Aviello G, Romano B, Scalisi C, Capasso F et al. (2008). Cannabidiol, extracted from Cannabis sativa, selectively inhibits inflammatory hypermotility in mice. Br J Pharmacol 154 : 1001 1008.
10. Collins SM (1996). The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 111 : 1683 1699.
11. Daddaoua A, Martinez-Plata E, Lopez-Posadas R, Vieites JM, Gonzalez M, Requena P et al. (2007). Active hexose correlated compound acts as a prebiotic and is antiinflammatory in rats with hapten-induced colitis. J Nutr 137 : 1222 1228.
12. Duncan M, Davison JS, Sharkey KA (2005). Review article: endocannabinoids and their receptors in the enteric nervous system. Aliment Pharmacol Ther 22 : 667 683.
13. Esposito G, Scuderi C, Savani C, Steardo L Jr., De Filippis D, Cottone P et al. (2007). Cannabidiol in vivo blunts beta-amyloid induced neuroinflammation by suppressing IL-1beta and iNOS expression. Br J Pharmacol 151 : 1272 1279.
14. Fernandes M, Schabarek A, Coper H, Hill R (1974). Modification of delta9-THC-actions by cannabinol and cannabidiol in the rat. Psychopharmacologia 38 : 329 338.
15. Fujioka Y, Metsugi Y, Ogawara K, Higaki K, Kimura T (2008). Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug. Int J Pharm 352 : 36 43.
16. Garcia-Planella E, Marin L, Domenech E, Bernal I, Manosa M, Zabana Y et al. (2007). Use of complementary and alternative medicine and drug abuse in patients with inflammatory bowel disease. Med Clin (Barc) 128 : 45 48.
17. Grisham MB, Benoit JN, Granger DN (1990). Assessment of leukocyte involvement during ischemia and reperfusion of intestine. Methods Enzymol 186 : 729 742.
18. Hayakawa K, Mishima K, Nozako M, Hazekawa M, Irie K, Fujioka M et al. (2007). Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism. J Neurochem 102 : 1488 1496.
19. Hayakawa K, Mishima K, Hazekawa M, Sano K, Irie K, Orito K et al. (2008). Cannabidiol potentiates pharmacological effects of Delta(9)- tetrahydrocannabinol via CB(1) receptor-dependent mechanism. Brain Res 1188 : 157 164.
20. Jacobson K, McHugh K, Collins SM (1997). The mechanism of altered neural function in a rat model of acute colitis. Gastroenterology 112 : 156 162.
21. Kaplan BL, Springs AE, Kaminski NE (2008). The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochem Pharmacol 76 : 726 737.
22. Karniol IG, Carlini EA (1973). Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol. Psychopharmacologia 33 : 53 70.
23. Karniol IG, Shirakawa I, Kasinski N, Pfeferman A, Carlini EA (1974). Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man. Eur J Pharmacol 28 : 172 177.
24. Kimball ES, Schneider CR, Wallace NH, Hornby PJ (2006). Agonists of cannabinoid receptor 1 and 2 inhibit experimental colitis induced by oil of mustard and by dextran sulfate sodium. Am J Physiol Gastrointest Liver Physiol 291 : G364 G371.
25. Kinoshita K, Hori M, Fujisawa M, Sato K, Ohama T, Momotani E et al. (2006). Role of TNF-alpha in muscularis inflammation and motility disorder in a TNBS-induced colitis model: clues from TNF-alpha-deficient mice. Neurogastroenterol Motil 18 : 578 588.
26. Krawisz JE, Sharon P, Stenson WF (1984). Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87 : 1344 1350.
27. Lal C, Ryan M, Tangri S, Silverberg MS, Gordon A, Steinhart AH (2007). Cannabis use by patients with inflammatory bowel disease. Gastroenterology 132 : A183.
28. Li X, Kaminski NE, Fischer LJ (2001). Examination of the immunosuppressive effect of delta9-tetrahydrocannabinol in streptozotocin- induced autoimmune diabetes. Int Immunopharmacol 1 : 699 712.
29. Lyman WD, Sonett JR, Brosnan CF, Elkin R, Bornstein MB (1989). Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol 23 : 73 81.
30. McHugh D, Tanner C, Mechoulam R, Pertwee RG, Ross RA (2008). Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinods: evidence for a site distinct from CB1 and CB2. Mol Pharmacol 73 : 441 450.
31. Malfait AM, Gallily R, Sumariwalla PF, Malik AS, Andreakos E, Mechoulam R et al. (2000). The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis. Proc Natl Acad Sci USA 97 : 9561 9566.
32. Massa F, Marsicano G, Hermann H, Cannich A, Monory K, Cravatt BF et al. (2004). The endogenous cannabinoid system protects against colonic inflammation. J Clin Invest 113 : 1202 1209.
33. Massi P, Vaccani A, Parolaro D (2006). Cannabinoids, immune system and cytokine network. Curr Pharm Des 12 : 3135 3146.
34. Mechoulam R (2005). Plant cannabinoids: a neglected pharmacological treasure trove. Br J Pharmacol 146 : 913 915.
35. Mechoulam R, Parker LA, Gallily R (2002). Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol 42 : 11S 19S.
36. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL (1989). Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96 : 795 803.
37. Murphy LL, Steger RW, Smith MS, Bartke A (1990). Effects of delta-9-tetrahydrocannabinol, cannabinol and cannabidiol, alone and in combinations, on luteinizing hormone and prolactin release and on hypothalamic neurotransmitters in the male rat. Neuroendocrinology 52 : 316 321.
38. Napimoga MH, Benatti BB, Lima FO, Alves PM, Campos AC, Pena-Dos-Santos DR et al. (2009). Cannabidiol decreases bone resorption by inhibiting RANK/RANKL expression and pro-inflammatory cytokines during experimental periodontitis in rats. Int Immunopharmacol 9 : 216 222.
39. Pertwee RG (2007). Cannabinoids and multiple sclerosis. Mol Neurobiol 36 : 45 59.
40. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. Br J Pharmacol 153 : 199 215.
41. Poli E, Lazzaretti M, Grandi D, Pozzoli C, Coruzzi G (2001). Morphological and functional alterations of the myenteric plexus in rats with TNBS-induced colitis. Neurochem Res 26 : 1085 1093.
42. Riedel G, Fadda P, McKillop-Smith S, Pertwee RG, Platt B, Robinson L (2009). Synthetic and plant-derived cannabinoid receptor antagonists show hypophagic properties in fasted and non-fasted mice. Br J Pharmacol 156 : 1154 1166.
43. Russo E, Guy GW (2006). A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66 : 234 246.
44. Srivastava MD, Srivastava BI, Brouhard B (1998). Delta9 tetrahydrocannabinol and cannabidiol alter cytokine production by human immune cells. Immunopharmacology 40 : 179 185.
45. Storr M, Keenan CM, Patel KD, Sharkey KA (2007). The cannabinoid-2 (Cb2) receptor mediates protection against TNBS colitis in mice. Gastroenterology 132 (Suppl. 2 A231.
46. Sykes AP, Bhogal R, Brampton C, Chander C, Whelan C, Parsons ME et al. (1999). The effect of an inhibitor of matrix metalloproteinases on colonic inflammation in a trinitrobenzenesulphonic acid rat model of inflammatory bowel disease. Aliment Pharmacol Ther 13 : 1535 1542.
47. Vann RE, Gamage TF, Warner JA, Marshall EM, Taylor NL, Martin BR et al. (2008). Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol. Drug Alcohol Depend 94 : 191 198.
48. Venkova K, Dunn ST, Adesina AM, Meerveld BG, Greenwood-Van Meerveld B (2000). Neuromuscular dysfunction in the jejunum and colon of human leukocyte antigen B27 transgenic rats. J Pharmacol Exp Ther 293 : 60 66.
49. Watzl B, Scuderi P, Watson RR (1991). Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med Biol 288 : 63 70.
50. Weiss L, Zeira M, Reich S, Har-Noy M, Mechoulam R, Slavin S et al. (2006). Cannabidiol lowers incidence of diabetes in non-obese diabetic mice. Autoimmunity 39 : 143 151.
51. Wells RW, Blennerhassett MG (2004). Persistent and selective effects of inflammation on smooth muscle cell contractility in rat colitis. Pflugers Arch 448 : 515 524.
52. Whittle BJ, Varga C, Berko A, Horvath K, Posa A, Riley JP et al. (2008). Attenuation of inflammation and cytokine production in rat colitis by a novel selective inhibitor of leukotriene A4 hydrolase. Br J Pharmacol 153 : 983 991.
53. Wright KL, Duncan M, Sharkey KA (2008). Cannabinoid CB2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol 153 : 263 270.
54. Zuardi AW, Teixeira NA, Karniol IC (1984). Pharmacological interaction of the effects of delta 9-trans-tetrahydrocannabinol and cannabidiol on serum corticosterone levels in rats. Arch Int Pharmacodyn Ther 269 : 12 19.